Gonzaga Aitor, Andreu Etelvina, Hernández-Blasco Luis M, Meseguer Rut, Al-Akioui-Sanz Karima, Soria-Juan Bárbara, Sanjuan-Gimenez Jose Carlos, Ferreras Cristina, Tejedo Juan R, Lopez-Lluch Guillermo, Goterris Rosa, Maciá Loreto, Sempere-Ortells Jose M, Hmadcha Abdelkrim, Borobia Alberto, Vicario Jose L, Bonora Ana, Aguilar-Gallardo Cristobal, Poveda Jose L, Arbona Cristina, Alenda Cristina, Tarín Fabian, Marco Francisco M, Merino Esperanza, Jaime Francisco, Ferreres José, Figueira Juan Carlos, Cañada-Illana Carlos, Querol Sergio, Guerreiro Manuel, Eguizabal Cristina, Martín-Quirós Alejandro, Robles-Marhuenda Ángel, Pérez-Martínez Antonio, Solano Carlos, Soria Bernat
Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Institute of Bioengineering, Miguel Hernández University, Elche, Spain.
Front Immunol. 2023 Sep 11;14:1232472. doi: 10.3389/fimmu.2023.1232472. eCollection 2023.
An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19's pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.
2019冠状病毒病（COVID-19）由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起，造成了前所未有的全球社会和经济影响以及大量死亡。在某些情况下，急性SARS-CoV-2感染可导致免疫异常，引发异常的固有免疫和适应性免疫反应。虽然大多数患者仅出现轻微症状且无需机械通气即可康复，但仍有相当比例的感染者会发展为严重的呼吸系统疾病，甚至可能致命。当疾病进展到非常严重的程度时，缺乏有效的治疗方法，加上对COVID-19发病机制的不完全了解，促使人们需要为高死亡风险患者开发创新的治疗方法。因此，我们研究了有前景的联合细胞疗法对预防重症患者死亡的潜在作用。
